Tylenol Extra Strength Liver Damage Litigation Fails On ‘Ambiguity’ Of Use
This article was originally published in The Tan Sheet
Executive Summary
McNeil says the verdict a New Jersey state court jury rendered “reflects the facts of this case” while the plaintiff’s lawyers contend the “heart” of the case – safety of using the drug according to the label directions – was not addressed.
You may also be interested in...
Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial
J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.
Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial
J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.